The most frequently observed adverse drug reactions (ADRs) reported in ≥5 percent of patients in two double-blind controlled clinical trials of Abilify Maintena were weight increases (9.0 percent), akathisia (7.9 percent), insomnia (5.8 percent), and injection site pain (5.1 percent).Abilify Maintena is the only dopamine D2 partial agonist in once-monthly, injectable form to receive marketing authorization for maintenance treatment in schizophrenia. Lundbeck generated revenue of approximately DKK 15 billion in 2012. 113 0 obj <> endobj It most commonly manifests as hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, and is accompanied by significant social or occupational dysfunction. Otsuka Pharmaceutical welcomes you to visit its global website at Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain diseases. This event, held in the stunning natural beauty of Tokushima, has increased in scale and renown each year. Onset of symptoms typically occurs in young adulthood, and the condition is chronic, often requiring lifelong treatment to mitigate symptoms.Relapse of schizophrenia refers to an exacerbation or acute psychotic break that is characterised primarily by the emergence of positive symptoms such as hallucinations, delusions and disordered thinking.Relapse can occur when a patient no longer responds to antipsychotic medication, does not take the medication as prescribed, or stops taking their medication altogether. Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.In pharmaceuticals, Otsuka is a leading firm in the challenging area of mental health and also has research programs for several under-addressed diseases including tuberculosis, a significant global public health issue. The number of participants now exceeds 2000, triple the number when the festival started, and the festival has grown to become a major event in Tokushima.Information in this news release was current as of the original release date.Otsuka and Lundbeck's Once-Monthly Abilify Maintena® (Aripiprazole) Now Approved in Europe for Maintenance Treatment of Schizophrenia in Adult Patients Stabilized with Oral Aripiprazole There are many reasons patients stop taking their medication, including poor insight about their illness, side effects from current treatments, complicated medication regimen or lack of support from family.It has been estimated that schizophrenia affects approximately one percent of the adult population in the U.S. and Europe, and approximately 24 million people worldwide.Schizophrenia places a significant burden on society. We have research centers in Denmark, China and the United States and production facilities in Italy, France, Mexico, China and Denmark. 137 0 obj <>/Filter/FlateDecode/ID[<3C8AC0E9B14F0A4AADE52C07534C09A3><7F388806C78065489A790C08404F8468>]/Index[113 46]/Info 112 0 R/Length 117/Prev 175620/Root 114 0 R/Size 159/Type/XRef/W[1 3 1]>>stream Abilify Maintena is indicated for maintenance treatment of schizophrenia in adult patients stabilized with oral aripiprazole.After the first injection, treatment with 10 mg to 20 mg oral aripiprazole should be continued for 14 consecutive days to maintain therapeutic aripiprazole concentrations during initiation of therapy.Schizophrenia is a disease characterized by a distortion in the process of thinking and of emotional responsiveness. 158 0 obj <>stream ABILIFY MAINTENA is only to be administered by intramuscular injection by a healthcare professional. Physicians now have an alternative treatment option, with a tolerability profile comparable to the well-established oral ABILIFY, to address the on-going need to reduce the risk of relapse in patients with schizophrenia.The European label states that Abilify Maintena is a powder and solvent for prolonged-release suspension for intra-muscular (IM) injection. 0 %%EOF endstream endobj startxref It is regarded among the most financially costly illnesses and is according to the World Health Organization (WHO), the 8th leading cause of DALYs (lost healthy years) worldwide among patients between the age of 15-44.Lundbeck and Otsuka established a global alliance in November 2011 to bring to bear their considerable experience and resources in the CNS area to introduce next-generation treatments for conditions such as schizophrenia, depression, Alzheimer's disease and alcohol dependency.Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Consolidated sales were approximately €10 billion or USD 13 billion for fiscal year 2012 (4/1/2012-3/31/2013). You may feel a little pain in your arm or buttock during your injection. ""Studies have shown that the early use of long-acting injectables can prevent a person with schizophrenia from experiencing a relapse,"The efficacy of Abilify Maintena was demonstrated in two double-blind, Phase III, randomized trials.